

Sepracor Inc.

Company Overview – November 12, 2009

Adrian Adams

President and CEO



Disclaimer Regarding Forward-looking Statements

The statements made in this presentation material are forward-looking statements based on management's assumptions and beliefs in light of information available up to the day of announcement, and involve both known and unknown risks and uncertainties.


Actual financial results may differ materially from those presented in this document, being dependent on a number of factors.

Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Overview of Sepracor Inc.


- ***Fully integrated***, research-based pharmaceutical company
- Current therapeutic focus: ***Respiratory & CNS***
- ***Primary care and specialty marketing*** with drug discovery and development infrastructure
- R&D pipeline: ***early-, mid-, and late-stage assets***
- ***Six products*** available in the U.S.
 - LUNESTA[®], XOPENEX[®] Inhalation Solution, XOPENEX HFA[®] and BROVANA[®]
 - Ciclesonide franchise – includes OMNARIS[®] Nasal Spray and ALVESCO[®] HFA Inhalation Aerosol
- **Royalty income from *three major partnered products***
 - ALLEGRA[®], CLARINEX[®] and XYZAL[®]/XUSAL[™]
- ***Strong cash position***
- **2008 total revenues of approximately *\$1.3 billion***

Sepracor Inc. – 25 Years of Evolution




Sepracor: Historical Financial Performance

Total Revenue Growth 2000 - 2008




GAAP Net Income (Loss) 2000 - 2008



Prior periods have been adjusted to reflect the impact of the adoption on January 1, 2009 of FASB Staff Position No. APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)* ("FSP APB 14-1"), FSP Emerging Issues Task Force No. 03-6-1, *Determining Whether Instruments Granted in Share-Based Payment Transactions are Participating Securities* ("FSP EITF 14-1"), and certain other immaterial adjustments as described in the Form 8-K filed with the SEC on May 14, 2009.


Sepracor Employee Base

Approximately 2,100 Employees



Sepracor's Product Portfolio by Contribution

2008 Product Revenues: ~\$1.3 B



Note: SPI revenues are for June to December 2008. ALVESCO revenues are for September to December 2008. OMNARIS revenues are for April to December 2008.

Corporate Priorities and Opportunities

Corporate / Commercial

- Drive ***strong product portfolio performance*** with continued focus on ***efficiencies, effectiveness and profitability***
- **Generate efficiencies from corporate restructuring** to continue to ***achieve cost savings and build foundation for the future***

Research & Development

- Successfully **execute *high-priority R&D initiatives*** to strengthen **pipeline** and enhance current franchises

Corporate Development & Licensing

- **Aggressively pursue corporate development and licensing opportunities** that enhance the portfolio and complement DSP's strategic direction

Financial

- Deliver ***sustainable earnings momentum*** and enhanced shareholder value

Commercial: Overview of 2009 Priorities

Achieve Financial Targets

- Meet or exceed top- and bottom-line targets
- Launch new direct-to-consumer campaigns for LUNESTA[®] and OMNARIS[®] Nasal Spray

Focus on Profitability

- Realize efficiencies from new commercial model implemented early 2009
- Focus on contracting profitability
- Maintain profitability of XOPENEX[®] Inhalation Solution and LUNESTA

Expand the Portfolio

- ALVESCO[®] primary care physician launch
- Prepare for STEDESA[™] launch

Maximize Capabilities

- Forecasting, incentives and targeting
- Build relationship management platform for all brands
- Commercial training and leadership development

Sepracor's Commercial Model

Context

- Recent *trends and macroeconomic environment* impacting pharmaceutical market
- *Reach and frequency model with multiple sales forces* is losing momentum
- Gain operating leverage with *new model that supports current and future portfolio*
- Foundation of *changes began in 2008*

Description

- Commercial model *organized into two business units* (Primary Care and Specialty)
- Sales representatives have *territory brand ownership* with no mirrored territories and *high accountability*

Potential Benefits

- Fosters entrepreneurial spirit and *“fast-acting, high-performance”* culture
- Enables *decision-making at lower levels* in headquarters and field
- *Focus remains on important compliance issues*

Product Ownership With Optimized Resources



Primary Care Physician (PCP) Focus

94,000 Targets

755 Sales Representatives

LUNESTA® / OMNARIS® Sales Representatives



Specialty Focus

43,000 Targets

295 Sales Representatives

XOPENEX® / ALVESCO® Sales Representatives



Home Health Care & Specialty Focus

19,000 Targets

142 Sales Representatives


BROVANA® Sales Representatives

Sales Representatives will be Market Driven


- Product, Disease State and Market Experts
- 100% Product Ownership and Accountability
- Pay for Performance
- Experts In Territory Analytics and Planning

Improvement in Field Productivity Metrics


Total Prescriptions (TRxs) / Representative



Net Sales / Representative



P1 Details / Representative



Improvement in Field Metrics

- TRxs per representative up 37%
- P1 details per representative up 24%
- Net Sales per representative up 31%

Source: IMS IPS, IMS NPA, Sepracor internal

LUNESTA®: Overview of Market and Product



Therapeutic Overview

- 30-40% of adults have some symptoms of insomnia within a year
- 15% of adults have chronic insomnia
- Chronic insomnia is more prevalent with age and among women


U.S. Market Opportunity

- Insomnia market size: \$4B+, 5% annual growth
- Highly competitive market with established generic options
- 1/3 of the volume prescription and 2/3 over-the-counter; 90% of the sales from prescription and 10% from over-the-counter

LUNESTA

- A non-narcotic sedative hypnotic indicated for sleep onset and sleep maintenance
- Activity on GABA-A receptor complex across $\alpha 1$, $\alpha 2$, and $\alpha 3$ receptor subtypes

LUNESTA® Performance



Performance Update

- Qtr3 '09 revenues of \$127.3 M and YTD revenues of \$418.9 M
- Overall insomnia market growth in single digits, driven principally by generic zolpidem



Promotional Priorities

- Promotional messages focus on the “Science of Sleep (GABA receptor activity differentiation)”, particularly versus zolpidem
- Targeted promotional spend with emphasis on margin improvement
- Continue online direct-to-consumer and relationship management programs designed to drive dialogue between patients and physicians about LUNESTA and improve compliance with prescription drug therapy

Data sources: IMS NSP Monthly, Sepracor internal. Audited promotion spending include DTC spending, detailing spending, and retail value of samples. Full Q3'09 Audited promotional spending is not available.

YTD denotes January through September 30, 2009

XOPENEX®: Overview of Market and Products



Xopenex®
brand of levalbuterol

Therapeutic Overview

- Current asthma prevalence is 28 M people
- 71% of patients are diagnosed

U.S. Market Opportunity


- Current short-acting beta-agonist (SABA) market (moving average total Sept '09): \$2.5B
- Annual Total Prescription growth rate: 4.4%
- Seasonal and competitive market with generic options
- 78% of patients are prescribed inhalers
- 26% of patients are prescribed nebulizers

XOPENEX Inhalation Solution and HFA Inhalation Aerosol


- A bronchodilator indicated for the treatment or prevention of acute bronchospasm in patients with reversible obstructive airway disease
- Only contains the therapeutically active (R)-isomer of albuterol

XOPENEX[®] - Stable Franchise Performance

XOPENEX Inhalation Solution Revs.



XOPENEX HFA Inhalation Aerosol Revs.



Performance Update

XOPENEX[®] Inhalation Solution

- Qtr3 '09 revenues of \$86.1 M and YTD revenues of \$294.2 M
- Increased contribution margins

XOPENEX HFA[®]

- Qtr3 '09 revenues of \$22.8 M and YTD revenues of \$57.7 M
- Increased contribution margins

Promotional Priorities

- New “Asthma” Sales team gives additional focus to XOPENEX family
- Increased detailing to loyalists and pediatricians
- Continued focus on unique single isomer chemical structure
- Drive patient starts with XoPack sample pack

YTD denotes January through September 30, 2009

BROVANA®: Overview of Market and Product



Twice-Daily
Brovana[®] 15
 mcg
 (arformoterol tartrate) Inhalation Solution

Sources: IMS, CDC, NHLBI, Sepracor Internal

Therapeutic Overview

- ~ 12 M people are diagnosed with chronic obstructive pulmonary disease (COPD)
- Risk factors include smoking, pollution and existing lung impairment


U.S. Market Opportunity

- Large Total Prescription (TRx) market for COPD: 22 M TRxs (moving average total July '09)
- Untapped market opportunity: currently only 1 M patients are treated with nebulized therapy
- Only two long-acting beta-agonist (LABA) nebulized products available
- Significant market volume in Medicare and Home Health Care

BROVANA

- An inhalation solution bronchodilator indicated for the maintenance treatment of COPD
- Clinical benefits include rapid onset and sustained bronchodilation

BROVANA® Volume Continues to Build



Data source: IMS DDD COT Monthly. BROVANA units received in mL then converted into package units divided by 2. Q3'09 Units were estimated using weekly DDD data

YTD denotes January through September 30, 2009

BROVANA Performance

- Q3 '09 revenues of \$18.5 M and YTD revenues of \$56.2 M
- Volume continues to build
- Unrestricted access at 93% of managed care lives
- Improved share of voice and awareness among targeted physicians
- Less restrictive Medicare coverage criteria for long-acting beta agonists became effective 12/1/09

Promotional Priorities

- Specialty Markets Business Unit provides greater focus for BROVANA
- Physician targeting focused on top prescribers



OMNARIS®: Overview of Market and Product



omnaris®
(ciclesonide) Nasal Spray, 50 mcg

Therapeutic Overview

- Allergic Rhinitis (AR) affects 65 M people
- Most patients suffer from Perennial Allergic Rhinitis (PAR) or both PAR and Seasonal Allergic Rhinitis (SAR)
- Strong association between AR and other respiratory disorders


U.S. Market Opportunity

- Current intranasal steroid (INS) market (moving average total Sept '09): ~ \$2B
- Annual Total Prescription growth rate: 1-3%
- Market is promotionally sensitive, which drives direct-to-consumer strategy

OMNARIS

- An inhaled nasal steroid indicated for treatment of nasal symptoms of SAR in patients ≥ 6 yrs and PAR in patients ≥ 12 yrs
- Prodrug activated after nasal administration that provides significant improvement in total nasal symptom score (TNSS), within 24-48 hours

OMNARIS® Nasal Spray - Continued Strong Uptake



Data source: IMS NPA Weekly. The INS Market is defined as the Inhaled Nasal Steroid Class (USC 28420). YTD denotes January through September 30, 2009

Performance Update

- Qtr3 '09 revenues of \$7.3 M and YTD revenues of \$22.3 M
- Total Prescription volume and share growth strong through spring allergy season
- Share growth during intranasal steroid low-season
- Patient awareness increasing through direct-to-consumer campaign



Promotional Priorities

- Continue to drive uptake with key specialists (e.g., allergists; ear, nose and throat specialists)
- Emphasis on consumer marketing as integral component of promotional strategy

ALVESCO®: Overview of Market and Products



Alvesco
(ciclesonide)
Inhalation Aerosol 80 mcg, 160 mcg

Therapeutic Overview

- Current asthma prevalence 28 M people
- 13 M people suffer from asthma attacks annually
- Therapy goals include reducing impairment by maintaining lung function


U.S. Market Opportunity

- Current inhaled corticosteroid market (ICS) (moving average total Sept '09): ~ \$1.4B
- Annual Total Prescription growth rate: 6%
- Programs that educate prescribers and patients about the role of inflammation in chronic asthma can improve compliance with treatment guidelines

ALVESCO

- An inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients ≥ 12 years old

ALVESCO® Volume Continues to Build



Data source: IMS NPA Weekly. The ICS market is defined as Inhaled Bronchial Steroid (USC 28410), exclude Pulmicort Respules and Budesonide.

Performance Update

- Positive prescription share and volume growth during asthma “low” season
- Broader primary care launch began in Qtr1, positive impact to New Prescription trends
- Strong share growth among key specialists (e.g., allergists, pulmonologists)

Promotional Priorities

- PCP promotional focus on site-activated efficacy
- Patient programs including starter kits with co-pay reduction cards to encourage initial trial
- Continued use of other relationship management programs

Sepracor's Product Patent Portfolio

- **XOPENEX[®] Inhalation Solution*** – August 20, 2012**
- **XOPENEX HFA[®]** – last patent expires in 2024
- **LUNESTA[®]** – Qtr3 2014; assumes patent-term and pediatric extensions
- **BROVANA[®]** – last patent expires 2021
- **OMNARIS[®] Nasal Spray** – composition of matter patent expires in October 2017; last patent expires October 2020
- **ALVESCO[®] HFA** – composition of matter expires in October 2017; last patent expires May 2018
- **STEDESA[™]** – patent-term extension could take composition of matter patent to late 2018/early 2019; additional patent applications are pending

*Mylan (Dey) is currently selling a generic version of the XOPENEX Inhalation Solution concentrate formulation.

** Generic entry date per settlement.

Research and Development Update

R&D Priorities

- **Successfully execute *high-priority R&D initiatives* to strengthen pipeline** and enhance current franchises

Late-Stage Research and Development Assets

- **STEDESA™ (eslicarbazepine acetate)** for adjunctive treatment of epilepsy under FDA review
- **OMNARIS® (ciclesonide) HFA** for the treatment of allergic rhinitis in Phase III development


STEDESA™ Market Opportunity

Market

- Approx. 2.7 M people in U.S. with epilepsy
- U.S. epilepsy treatment mkt. est. \$3.5 B

Anti-Epileptic Drugs* – Total Prescriptions (TRxs)

86 million Rxs in 2008 with a 7.5% CAGR '02-'08



Target Profile

- Efficacy
 - Clear dose-response correlation
 - Marked, sustained seizure reduction
- Tolerability/Safety
 - Favorable tolerability and safety profiles
 - Relatively low risks regarding incidence of rash, weight gain or hyponatremia in study population
- Health Outcomes
 - Significant improvements in quality of life over one-year treatment period

Regulatory Milestones

- Submitted NDA to FDA on March 30, 2009
- FDA action date January 30, 2010

Ongoing Development Program

- U.S. Phase III adult monotherapy study initiated
- Pediatric and additional indication programs of Bipolar disorder and Neuropathic Pain are in planning stages

Sources: IMS NPA and IMS Healthplan analysis, 2006-2007, n=73,399 projected to U.S. insured population, Sepracor Internal

Eslicarbazepine Acetate Clinical Development Program

Phase III Combined Analysis


- 3 Phase III studies with common design testing doses of 400 mg, 800 mg and 1200 mg once-daily throughout a 12-week maintenance period
- Randomized, double-blind, placebo-controlled trials
- 1,049 adult patients with refractory partial-onset seizures ≥ 4 seizures per 28 days on a stable regimen of 1 to 3 concomitant AEDs
- Multinational program: 125 sites in 23 countries

Results from One-Year Open-Label Extension Study


	BIA-2093-301	BIA-2093-302	BIA-2093-303
Number of patients enrolled (Total 833)	314	325	194
Patients who completed 1 year (Total 612)	239	223	150
Retention Rate (73.5%)	76.1%	68.6%	78.5%
Median dose of ESL	800 mg	800 mg	800 mg

Eslicarbazepine Acetate Phase III Results

Mean Relative (%) Reduction From Combined Analysis




Mean Quality of Life in Epilepsy Inventory-31 (QOLIE-31) After 1-Year Treatment or Discontinuation



Data on file – Phase III – Integrated Analysis studies 301, 302 and 303. QOLIE Scores from individual study 2093-301 Part 2.

OMNARIS® HFA for Allergic Rhinitis

OMNARIS HFA nasal aerosol



- ✓ Automatic dose counter
- ✓ Powerful spray delivers medication deep into nasal passages
- ✓ Compact, portable device

Opportunity

- Intranasal corticosteroid market approximately \$2 B
- Approx. 20% of patients discontinue use of nasal medications due to tolerability issues
- Prior to chlorofluorocarbon (CFC) phase-out, intranasal steroid aerosols represented approx. 25% of Total Prescription volume

Target Profile

- Potential to be first available corticosteroid formulated in a hydrofluoroalkane (HFA) nasal aerosol
- Formulation designed for no run-off or dripping, which is a common problem with most aqueous formulations

Development Timeline

- Phase III SAR results complete
- Initiate Phase III PAR Qtr3 2009
- Potential NDA submission Qtr1 '11

OMNARIS® HFA Phase III SAR Study Results

Study Design

- Evaluated safety and efficacy of 80 mcg and 160 mcg of ciclesonide vs. placebo in patients with seasonal allergic rhinitis (SAR)
- 707 adults and adolescents randomized over two weeks

Results

- **Primary efficacy endpoint:** change from baseline in patient-reported *AM and PM reflective total nasal symptom scores (TNSS)* over two weeks ($p < 0.0001$ for both doses)
- **Key secondary endpoints:**
 - Change from baseline in patient-reported *AM and PM instantaneous TNSS* over two weeks ($p < 0.0001$ for both doses)
 - Change from baseline in patient-reported *AM and PM reflective total ocular symptom scores* ($P < 0.001$ for both doses)
- **Overall adverse events** for 80 mcg group and 160 mcg group comparable to placebo

Corporate Development & Licensing (CD&L) Update

CD&L Priorities

Aggressively pursue corporate development and licensing opportunities that enhance the portfolio and complement DSP's strategic direction


Key Sepracor Partners

Out-licensed

In-licensed

Note: 3M is a technology partner of Sepracor

Current Priorities and Recent CD&L Activity (24 Months)



*Includes products and companies, both public and private.





Financial Highlights Qtr3 and YTD 2009

Financial Update

Third Quarter 2009 Financial Results

January-September Year-to-Date 2009 Financial Highlights

2009 Continued Strong Non-GAAP Earnings Momentum




YTD denotes January through September 30, 2009

Year-To-Date (YTD) Jan.-Sept. 30, 2009 Summary of Results (Non-GAAP)

	YTD 2009		YTD 2008	
	\$ Millions	% of Rev.	\$ Millions	% of Rev.
Revenue	927		923	
Margin	843	91%	835	90%
R&D	161	17%	178	19%
SG&A	435	47%	590	64%
Net Income	246	27%	82	9%
Diluted EPS	\$2.16		\$0.70	
Shares Outstanding	114 M		116 M	

Strong Balance Sheet Improvement



Cash and short- and long-term investments were approximately \$742 M at Sept. 30, 2009

* The remaining \$186M of 2024 bonds and \$100M of 2010 bonds are expected to be put back to the company in October and November respectively.

2009 Financial Guidance Summary – Non-GAAP*

<i>\$ in millions except per share amounts</i>	2008 Actual Results	Original 2009 Guidance	Revised 2009 Guidance (as of July 24, 2009)
Revenue	\$1,292	\$1,150 - \$1,250	\$1,225 - \$1,275
R&D	\$237	\$210	\$210
SG&A	\$759	\$600	\$600
EPS (fully diluted)	\$1.63	\$2.10 - \$2.70	\$2.55 - \$2.90
Shares Outstanding	116 M	116 M	114.5 M
Cash & Equiv.	\$766	\$525 - \$600	\$550 - \$600
Debt (par value)	\$530	\$148	\$100
Cash Tax Rate	1.1%	2.5%	3.0%

*A reconciliation of GAAP to non-GAAP guidance calculations is located in the company's second quarter 2009 earnings press release dated July 24, 2009, which can be found on Sepracor's web site in the "For Investors" section.

Delivering on Our 2009 Corporate Objectives

Drive strong top-line product portfolio performance

- Continued steady product performance

Generate efficiencies from corporate restructuring

- Achieving cost-savings from our new commercial model

Advanced two high-priority R&D assets

- Submitted STEDESA™ NDA to FDA for adjunctive treatment of epilepsy
- Successfully completed OMNARIS® HFA Phase III study in seasonal allergic rhinitis and initiated Phase III perennial allergic rhinitis study in September

Aggressively pursue corporate development and licensing opportunities

- Continuing to actively pursue opportunities in 2009, leveraging improved balance sheet

Deliver sustainable earnings momentum and enhanced shareholder value

- Delivering enhanced productivity and improved expense ratios

Key Benefits of DSP's Acquisition of Sepracor

Establishes international platform

- Access to fully integrated U.S. and Canadian pharmaceutical platforms with a successful, experienced management team and talented employee base
- Extensive R&D organization with expertise in complementary therapeutic areas providing an enhanced pipeline of clinical candidates

Expands scale of pharmaceutical business

- Established, successful commercial network in the U.S. and Canada
- Significantly enhances sales capabilities

Reinforces product pipeline portfolio

Potential to accelerate penetration and maximize sales of lurasidone in the U.S.

Questions and Answers